Skip to content

Girls, women and hormonal context

TL;DR — Girls meet ADHD criteria at just under half the rate of boys, while the sex ratio approaches equality in adulthood; referral setting, internalizing comorbidity and less overt symptoms materially shape recognition (Hinshaw 2022, PMID 34231220). Inattention and compensatory strategies can delay referral without implying milder impairment (Young 2020, PMID 32787804). Menstrual-cycle, pregnancy, postpartum and menopause questions are clinically salient but supported by a much smaller evidence base than general ADHD treatment. Reproductive-stage decisions therefore require separating established medication safety data from mechanistic hypotheses and lived reports.

Recognition gap

Mechanism Consequence Evidence boundary
Less disruptive presentation Lower referral probability Not universal; clinical samples are selected
Internalizing comorbidity ADHD symptoms may be attributed to anxiety/depression Both disorders may be present
Compensation/masking Later collapse when demands rise Hard to measure retrospectively
Male-normed expectations Clinician and teacher detection bias Instruments still require validation

Hinshaw and colleagues concluded that girls are diagnosed at just under half the rate of boys, with a ratio closer to equality in adulthood; females more often show inattention and internalizing problems, while referral source strongly modifies observed sex differences (Hinshaw 2022, PMID 34231220).

Outcomes requiring specific attention

Female longitudinal evidence identifies serious relationship impairment, self-harm, unplanned pregnancy and comorbid psychopathology as priority outcomes rather than peripheral issues (Hinshaw 2022, PMID 34231220). These associations do not mean every girl or woman follows the same course.

Hormonal and reproductive stages

Menstrual-cycle symptom fluctuation is biologically plausible and reported, but studies remain small and heterogeneous. Pregnancy and postpartum reviews must balance untreated impairment, medication exposure, confounding by indication and maternal outcomes (Scoten 2024, PMID 38432409).

Evidence around menopause is particularly limited. Extrapolation from younger adults should be labeled as extrapolation, especially where cardiovascular risk, sleep and polypharmacy change.

How to read the evidence

  • Diagnostic case–control separation is not the same as accuracy among referred patients.
  • Symptom change is not interchangeable with functional improvement.
  • Short randomized trials estimate acute efficacy, not decades-long benefit or harm.
  • Observational within-person and target-trial designs reduce some confounding but remain nonrandomized.
  • Parent, teacher, clinician, self-report and objective tasks measure different vantage points.
  • Statistical significance does not establish a patient-important effect.
  • Population averages should not be converted into deterministic individual predictions.
  • Absence of evidence in a subgroup is not evidence of identical effects.

Minimum standards for the next evidence generation

  1. Prespecify one primary outcome and its clinically important threshold.
  2. Report symptoms, function, quality of life and harms separately.
  3. Use clinically relevant comparators rather than only healthy controls.
  4. Retain and report participants who discontinue treatment.
  5. Test generalization across sex, age, ancestry, comorbidity and setting.
  6. Separate model development, internal validation and external validation.
  7. Declare medication exposure, concomitant care and rater blinding.
  8. Make null and contradictory results visible rather than averaging away design differences.

Recurring evidence gaps

  • Females, older adults and people with complex comorbidity remain underrepresented.
  • Functional outcomes are measured less consistently than core symptoms.
  • Follow-up usually ends before major educational or occupational transitions.
  • Comparator choice often makes effects look more or less specific than they are.
  • Treatment discontinuation and switching weaken long-term causal contrasts.
  • Independent replication is uncommon for biomarkers and digital interventions.

Retrieved evidence map

The following records were retrieved through this page’s six live PubMed searches. Inclusion here means the record is directly relevant to the page’s scope; it does not imply equal quality or endorsement of its conclusions.

Citation Indexed study lens Directly studied question/title Interpretation boundary
Hinshaw 2022, PMID 34231220 Journal Article, Review Annual Research Review: Attention-deficit/hyperactivity disorder in girls and women: underrepresentation, longitudinal processes, and key directions. Interpret within its sampled population and comparator
Young 2020, PMID 32787804 Journal Article, Research Support, Non-U.S. Gov't Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women. Interpret within its sampled population and comparator
Scoten 2024, PMID 38432409 Journal Article, Practice Guideline Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period. Interpret within its sampled population and comparator
Auvin 2018, PMID 30178479 Journal Article, Systematic Review Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission. Interpret within its sampled population and comparator
Kok 2020, PMID 32946507 Journal Article, Systematic Review The female side of pharmacotherapy for ADHD-A systematic literature review. Interpret within its sampled population and comparator
Young 2024, PMID 39494848 Journal Article, Review A systematic review and meta-analysis comparing the severity of core symptoms of attention-deficit hyperactivity disorder in females and males. Interpret within its sampled population and comparator
Wynchank 2025, PMID 41115846 Journal Article, Review Practical tools for female-specific ADHD: The impact of hormonal fluctuations in clinical practice and from the literature. Interpret within its sampled population and comparator
Thomas 2015, PMID 25733754 Comparative Study, Journal Article Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Interpret within its sampled population and comparator
de Schipper 2015, PMID 26428005 Journal Article, Research Support, Non-U.S. Gov't Towards an ICF core set for ADHD: a worldwide expert survey on ability and disability. Interpret within its sampled population and comparator
Hendriksen 2015, PMID 25976065 Journal Article Diagnostic overshadowing in a population of children with neurological disabilities: A cross sectional descriptive study on acquired ADHD. Interpret within its sampled population and comparator
Osianlis 2025, PMID 40251875 Journal Article, Systematic Review ADHD and Sex Hormones in Females: A Systematic Review. Interpret within its sampled population and comparator
Eng 2024, PMID 38039899 Journal Article, Review Attention-deficit/hyperactivity disorder and the menstrual cycle: Theory and evidence. Interpret within its sampled population and comparator
Wynchank 2025, PMID 41517370 Journal Article, Review Menstrual Cycle-Related Hormonal Fluctuations in ADHD: Effect on Cognitive Functioning-A Narrative Review. Interpret within its sampled population and comparator
de Jong 2023, PMID 38152361 Journal Article Female-specific pharmacotherapy in ADHD: premenstrual adjustment of psychostimulant dosage. Interpret within its sampled population and comparator
Kooij 2025, PMID 40692967 Journal Article, Review Research advances and future directions in female ADHD: the lifelong interplay of hormonal fluctuations with mood, cognition, and disease. Interpret within its sampled population and comparator
Roberts 2018, PMID 29197795 Journal Article, Research Support, N.I.H., Extramural Reproductive steroids and ADHD symptoms across the menstrual cycle. Interpret within its sampled population and comparator
Osianlis 2026, PMID 41330200 Journal Article, Research Support, Non-U.S. Gov't ADHD in females: Survey findings on symptoms across hormonal life stages. Interpret within its sampled population and comparator
Bürger 2024, PMID 38678676 Journal Article Perceived associations between the menstrual cycle and Attention Deficit Hyperactivity Disorder (ADHD): A qualitative interview study exploring lived experiences. Interpret within its sampled population and comparator
Zaritsky 2026, PMID 41451846 Journal Article Changes in ADHD Symptoms and Mood Across the Menstrual Cycle in Females Treated With Stimulants: A Pilot Study. Interpret within its sampled population and comparator
Broughton 2025, PMID 40528384 Journal Article Increased risk of provisional premenstrual dysphoric disorder (PMDD) among females with attention-deficit hyperactivity disorder (ADHD): cross-sectional survey study. Interpret within its sampled population and comparator
Kennedy 2026, PMID 42274016 Journal Article, Scoping Review Menstrual health and Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms: A scoping review. Interpret within its sampled population and comparator
Ji 2020, PMID 31664451 Journal Article, Research Support, N.I.H., Extramural Association of Cord Plasma Biomarkers of In Utero Acetaminophen Exposure With Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood. Interpret within its sampled population and comparator
Bang Madsen 2023, PMID 36759544 Journal Article, Research Support, N.I.H., Extramural In utero exposure to ADHD medication and long-term offspring outcomes. Interpret within its sampled population and comparator
Li 2020, PMID 32333292 Journal Article, Research Support, N.I.H., Extramural Associations of Prescribed ADHD Medication in Pregnancy with Pregnancy-Related and Offspring Outcomes: A Systematic Review. Interpret within its sampled population and comparator
Masarwa 2018, PMID 29688261 Journal Article, Meta-Analysis Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity Disorder and Autistic Spectrum Disorder: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Cohort Studies. Interpret within its sampled population and comparator
Tai 2025, PMID 41083615 Journal Article, Systematic Review Maternal and offspring outcomes associated with prescribed ADHD medication in pregnancy: a systematic review. Interpret within its sampled population and comparator
Wynchank 2026, PMID 42018215 Journal Article, Review Pharmacological Management of ADHD in Women Across Perimenopause, Menopause and Post-Menopause. Interpret within its sampled population and comparator
Jakobsdóttir Smári 2025, PMID 40903825 Journal Article Perimenopausal symptoms in women with and without ADHD: A population-based cohort study. Interpret within its sampled population and comparator
Krebs 2025, PMID 41361438 Journal Article, Review Integrative literature review - the impact of ADHD across women's lifespan. Interpret within its sampled population and comparator
Craddock 2024, PMID 39025117 Journal Article Being a Woman Is 100% Significant to My Experiences of Attention Deficit Hyperactivity Disorder and Autism: Exploring the Gendered Implications of an Adulthood Combined Autism and Attention Deficit Hyperactivity Disorder Diagnosis. Interpret within its sampled population and comparator
Pines 2016, PMID 26914101 Journal Article Midlife ADHD in women: any relevance to menopause? Interpret within its sampled population and comparator
Antoniou 2021, PMID 34483739 Journal Article, Review ADHD Symptoms in Females of Childhood, Adolescent, Reproductive and Menopause Period. Interpret within its sampled population and comparator

Open questions

  • Which referral and rating procedures reduce missed cases without sacrificing specificity? (Hinshaw 2022, PMID 34231220)
  • How large and reproducible are within-person symptom changes across menstrual phases? (Young 2020, PMID 32787804)
  • What are comparative maternal and offspring outcomes under treated versus untreated ADHD in pregnancy? (Scoten 2024, PMID 38432409)

References

  1. Hinshaw et al. Annual Research Review: Attention-deficit/hyperactivity disorder in girls and women: underrepresentation, longitudinal processes, and key directions. Journal of child psychology and psychiatry, and allied disciplines. 2022;63:484-496. PMID 34231220
  2. Young et al. Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women. BMC psychiatry. 2020;20:404. PMID 32787804
  3. Scoten et al. Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period. American journal of obstetrics and gynecology. 2024;231:19-35. PMID 38432409
  4. Auvin et al. Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission. Epilepsia. 2018;59:1867-1880. PMID 30178479
  5. Kok et al. The female side of pharmacotherapy for ADHD-A systematic literature review. PloS one. 2020;15:e0239257. PMID 32946507
  6. Young et al. A systematic review and meta-analysis comparing the severity of core symptoms of attention-deficit hyperactivity disorder in females and males. Psychological medicine. 2024;54:3763-3784. PMID 39494848
  7. Wynchank et al. Practical tools for female-specific ADHD: The impact of hormonal fluctuations in clinical practice and from the literature. European psychiatry : the journal of the Association of European Psychiatrists. 2025;69:e1. PMID 41115846
  8. Thomas et al. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015;135:e994-1001. PMID 25733754
  9. de Schipper et al. Towards an ICF core set for ADHD: a worldwide expert survey on ability and disability. European child & adolescent psychiatry. 2015;24:1509-21. PMID 26428005
  10. Hendriksen et al. Diagnostic overshadowing in a population of children with neurological disabilities: A cross sectional descriptive study on acquired ADHD. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 2015;19:521-4. PMID 25976065
  11. Osianlis et al. ADHD and Sex Hormones in Females: A Systematic Review. Journal of attention disorders. 2025;29:706-723. PMID 40251875
  12. Eng et al. Attention-deficit/hyperactivity disorder and the menstrual cycle: Theory and evidence. Hormones and behavior. 2024;158:105466. PMID 38039899
  13. Wynchank et al. Menstrual Cycle-Related Hormonal Fluctuations in ADHD: Effect on Cognitive Functioning-A Narrative Review. Journal of clinical medicine. 2025;15. PMID 41517370
  14. de Jong et al. Female-specific pharmacotherapy in ADHD: premenstrual adjustment of psychostimulant dosage. Frontiers in psychiatry. 2023;14:1306194. PMID 38152361
  15. Kooij et al. Research advances and future directions in female ADHD: the lifelong interplay of hormonal fluctuations with mood, cognition, and disease. Frontiers in global women's health. 2025;6:1613628. PMID 40692967
  16. Roberts et al. Reproductive steroids and ADHD symptoms across the menstrual cycle. Psychoneuroendocrinology. 2018;88:105-114. PMID 29197795
  17. Osianlis et al. ADHD in females: Survey findings on symptoms across hormonal life stages. Journal of psychiatric research. 2026;193:208-215. PMID 41330200
  18. Bürger et al. Perceived associations between the menstrual cycle and Attention Deficit Hyperactivity Disorder (ADHD): A qualitative interview study exploring lived experiences. Sexual & reproductive healthcare : official journal of the Swedish Association of Midwives. 2024;40:100975. PMID 38678676
  19. Zaritsky et al. Changes in ADHD Symptoms and Mood Across the Menstrual Cycle in Females Treated With Stimulants: A Pilot Study. Journal of attention disorders. 2026;30:329-341. PMID 41451846
  20. Broughton et al. Increased risk of provisional premenstrual dysphoric disorder (PMDD) among females with attention-deficit hyperactivity disorder (ADHD): cross-sectional survey study. The British journal of psychiatry : the journal of mental science. 2025;226:410-417. PMID 40528384
  21. Kennedy et al. Menstrual health and Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms: A scoping review. Women's health (London, England). 2026;22:17455057261460285. PMID 42274016
  22. Ji et al. Association of Cord Plasma Biomarkers of In Utero Acetaminophen Exposure With Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood. JAMA psychiatry. 2020;77:180-189. PMID 31664451
  23. Bang Madsen et al. In utero exposure to ADHD medication and long-term offspring outcomes. Molecular psychiatry. 2023;28:1739-1746. PMID 36759544
  24. Li et al. Associations of Prescribed ADHD Medication in Pregnancy with Pregnancy-Related and Offspring Outcomes: A Systematic Review. CNS drugs. 2020;34:731-747. PMID 32333292
  25. Masarwa et al. Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity Disorder and Autistic Spectrum Disorder: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Cohort Studies. American journal of epidemiology. 2018;187:1817-1827. PMID 29688261
  26. Tai et al. Maternal and offspring outcomes associated with prescribed ADHD medication in pregnancy: a systematic review. Archives of women's mental health. 2025;28:1425-1446. PMID 41083615
  27. Wynchank et al. Pharmacological Management of ADHD in Women Across Perimenopause, Menopause and Post-Menopause. Drugs & aging. 2026;43:385-395. PMID 42018215
  28. Jakobsdóttir Smári et al. Perimenopausal symptoms in women with and without ADHD: A population-based cohort study. European psychiatry : the journal of the Association of European Psychiatrists. 2025;68:e133. PMID 40903825
  29. Krebs et al. Integrative literature review - the impact of ADHD across women's lifespan. BMC women's health. 2025;25:593. PMID 41361438
  30. Craddock. Being a Woman Is 100% Significant to My Experiences of Attention Deficit Hyperactivity Disorder and Autism: Exploring the Gendered Implications of an Adulthood Combined Autism and Attention Deficit Hyperactivity Disorder Diagnosis. Qualitative health research. 2024;34:1442-1455. PMID 39025117
  31. Pines. Midlife ADHD in women: any relevance to menopause? Climacteric : the journal of the International Menopause Society. 2016;19:423-5. PMID 26914101
  32. Antoniou et al. ADHD Symptoms in Females of Childhood, Adolescent, Reproductive and Menopause Period. Materia socio-medica. 2021;33:114-118. PMID 34483739